Abstract

The Contractor shall perform clinical evaluations of treatment regimens utilizing activated leukocytes sponsored by the Division of Cancer Treatment, NCI, under an investigational new drug application (IND). Specifically, the Contractor shall: 1) determine the antitumor activity of activating agents in combination with activated leukocytes in a variety of human cancers in patients with advanced disease and minimal prior therapy; 2) define the toxicities of activating agents administered in combination with activated leukocytes to patients with advanced cancer; 3) evaluate new methods for activation of leukocytes and determine the antitumor activity of activated leukocytes generated using the new methodology.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
Division of Cancer Treatment (NCI)
Type
Research and Development Contracts (N01)
Project #
N01CM073704-000
Application #
3614793
Study Section
Project Start
1987-06-30
Project End
1991-06-29
Budget Start
1987-06-30
Budget End
1988-06-29
Support Year
Fiscal Year
1987
Total Cost
Indirect Cost

  Institution

Name
Loyola University Chicago
Department
Type
Schools of Medicine
DUNS #
791277940
City
Maywood
State
IL
Country
United States
Zip Code
60153

  Publications

Atkins, M B; Lotze, M T; Dutcher, J P et al. (1999) High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 17:2105-16
Hawkins, M J; Atkins, M B; Dutcher, J P et al. (1994) A phase II clinical trial of interleukin-2 and lymphokine-activated killer cells in advanced colorectal carcinoma. J Immunother Emphasis Tumor Immunol 15:74-8
Sparano, J A; Fisher, R I; Weiss, G R et al. (1994) Phase II trials of high-dose interleukin-2 and lymphokine-activated killer cells in advanced breast carcinoma and carcinoma of the lung, ovary, and pancreas and other tumors. J Immunother Emphasis Tumor Immunol 16:216-23
Sparano, J A; Fisher, R I; Sunderland, M et al. (1993) Randomized phase III trial of treatment with high-dose interleukin-2 either alone or in combination with interferon alfa-2a in patients with advanced melanoma. J Clin Oncol 11:1969-77
Sosman, J A; Weiss, G R; Margolin, K A et al. (1993) Phase IB clinical trial of anti-CD3 followed by high-dose bolus interleukin-2 in patients with metastatic melanoma and advanced renal cell carcinoma: clinical and immunologic effects. J Clin Oncol 11:1496-505
Dutcher, J P; Gaynor, E R; Boldt, D H et al. (1991) A phase II study of high-dose continuous infusion interleukin-2 with lymphokine-activated killer cells in patients with metastatic melanoma. J Clin Oncol 9:641-8
Margolin, K A; Aronson, F R; Sznol, M et al. (1991) Phase II trial of high-dose interleukin-2 and lymphokine-activated killer cells in Hodgkin's disease and non-Hodgkin's lymphoma. J Immunother (1991) 10:214-20
Sobotka, P A; McMannis, J; Fisher, R I et al. (1990) Effects of interleukin 2 on cardiac function in the isolated rat heart. J Clin Invest 86:845-50
Parkinson, D R; Fisher, R I; Rayner, A A et al. (1990) Therapy of renal cell carcinoma with interleukin-2 and lymphokine-activated killer cells: phase II experience with a hybrid bolus and continuous infusion interleukin-2 regimen. J Clin Oncol 8:1630-6
Parkinson, D R; Abrams, J S; Wiernik, P H et al. (1990) Interleukin-2 therapy in patients with metastatic malignant melanoma: a phase II study. J Clin Oncol 8:1650-6

Showing the most recent 10 out of 15 publications